Drug
Reltodecacog Alfa
Reltodecacog Alfa: highest development phase Phase 3, developed by VarmX B.V.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- VarmX B.V.
Trials
| Drug | Phase | Indication |
|---|---|---|
| Reltodecacog alfa NCT07288489 | Phase 3 | Blood Loss, Surgical |
Latest
No recent events.
Follow Reltodecacog Alfa on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.